TerminatedInterventionalPhase 3Last updated May 25, 2022

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial

Overview

ClinicalTrials.gov ID: NCT04400799
Lead Sponsor: University of ZurichOTHER
Brief Summary: The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
Study Type

Status

Study Record Dates

NCT04520620Withdrawn

Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention

NCT04366960Completed

Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients

NCT04406389Terminated

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04646655Completed

Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19

NCT04345848Terminated

Preventing COVID-19 Complications With Low- and High-dose Anticoagulation

NCT04492254Terminated

Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients